Tnf Pharmaceuticals, Stock Fundamentals
| TNFA Stock | 1.27 0.09 6.62% |
TNF Pharmaceuticals, fundamentals help investors to digest information that contributes to TNF Pharmaceuticals,'s financial success or failures. It also enables traders to predict the movement of TNF Stock. The fundamental analysis module provides a way to measure TNF Pharmaceuticals,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TNF Pharmaceuticals, stock.
At present, TNF Pharmaceuticals,'s Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 478.3 K, whereas Depreciation And Amortization is forecasted to decline to about 7.8 M. TNF | Select Account or Indicator |
TNF Pharmaceuticals, Company Return On Equity Analysis
TNF Pharmaceuticals,'s Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current TNF Pharmaceuticals, Return On Equity | -2.98 |
Most of TNF Pharmaceuticals,'s fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TNF Pharmaceuticals, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
TNF Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, TNF Pharmaceuticals, has a Return On Equity of -2.9763. This is 87.58% lower than that of the Pharmaceuticals sector and 91.84% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
TNF Pharmaceuticals, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining TNF Pharmaceuticals,'s current stock value. Our valuation model uses many indicators to compare TNF Pharmaceuticals, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across TNF Pharmaceuticals, competition to find correlations between indicators driving TNF Pharmaceuticals,'s intrinsic value. More Info.TNF Pharmaceuticals, is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . At present, TNF Pharmaceuticals,'s Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the TNF Pharmaceuticals,'s earnings, one of the primary drivers of an investment's value.TNF Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TNF Pharmaceuticals,'s direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TNF Pharmaceuticals, could also be used in its relative valuation, which is a method of valuing TNF Pharmaceuticals, by comparing valuation metrics of similar companies.TNF Pharmaceuticals, is currently under evaluation in return on equity category among its peers.
TNF Pharmaceuticals, Current Valuation Drivers
We derive many important indicators used in calculating different scores of TNF Pharmaceuticals, from analyzing TNF Pharmaceuticals,'s financial statements. These drivers represent accounts that assess TNF Pharmaceuticals,'s ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of TNF Pharmaceuticals,'s important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 19.5K | 224.5K | 2.2M | 2.5M | 2.9M | 3.1M | |
| Enterprise Value | 507.0K | (14.3M) | 1.8M | 1.9M | 313.9K | 329.6K |
TNF Fundamentals
| Return On Equity | -2.98 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | (9.48 M) | ||||
| Shares Outstanding | 2.37 M | ||||
| Shares Owned By Insiders | 6.44 % | ||||
| Shares Owned By Institutions | 39.87 % | ||||
| Number Of Shares Shorted | 279.28 K | ||||
| Price To Book | 0.44 X | ||||
| EBITDA | (4 M) | ||||
| Net Income | (4 M) | ||||
| Total Debt | 48.87 K | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (12.98 M) | ||||
| Short Ratio | 4.97 X | ||||
| Earnings Per Share | (10.48) X | ||||
| Beta | 2.67 | ||||
| Market Capitalization | 3.13 M | ||||
| Total Asset | 17.86 M | ||||
| Retained Earnings | (101.98 M) | ||||
| Working Capital | 828.25 K | ||||
| Net Asset | 17.86 M |
About TNF Pharmaceuticals, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TNF Pharmaceuticals,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TNF Pharmaceuticals, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TNF Pharmaceuticals, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 304.8 K | 320 K | |
| Research And Ddevelopement To Revenue | 0.57 | 0.31 | |
| Capex To Revenue | 0.04 | 0.03 | |
| Revenue Per Share | 251.34 | 238.77 | |
| Ebit Per Revenue | (4.62) | (4.39) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether TNF Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of TNF Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tnf Pharmaceuticals, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tnf Pharmaceuticals, Stock:Check out TNF Pharmaceuticals, Piotroski F Score and TNF Pharmaceuticals, Altman Z Score analysis. For information on how to trade TNF Stock refer to our How to Trade TNF Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TNF Pharmaceuticals,. If investors know TNF will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TNF Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.48) | Return On Assets (0.32) | Return On Equity (2.98) |
The market value of TNF Pharmaceuticals, is measured differently than its book value, which is the value of TNF that is recorded on the company's balance sheet. Investors also form their own opinion of TNF Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is TNF Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TNF Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect TNF Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TNF Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if TNF Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TNF Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.